SJP Biotec GmbH | Precision Oncology | RAS-MAPK & Translation Biology | Switzerland | Remote-Flexible About SJP Biotec SJP Biotec GmbH is a clinical-stage precision oncology company pioneering a first-in-class Selective Translation Regulatory Inhibitor (STRI) platform powered to overcome treatment resistance in refractory cancers. Founded in 2024, SJP targets RAS‑driven, hormone‑receptor‑positive, and immune‑refractory tumors with a novel pipeline of small molecules developed in our lab and ready to proceed with regulatory‑grade trials. Backed by a Scientific Advisory Board that includes world‑leading authorities in RAS and breast cancer biology, and immuno‑oncology, SJP has established clinical partnerships with leading medical centres worldwide including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill, to name a few. The Opportunity This is a stimulating and unique opportunity to join a scientifically exceptional, capital‑efficient biotech company doing groundbr...